氯雷他定糖浆市场：现状分析与预测（2022-2030）

氯雷他定糖浆市场因其商业化、安全性高、处方不昏昏等特点受到各年龄段消费者的青睐，预计将稳定增长在2%左右。 此外，人们对过敏及其对健康的影响、城市化、导致接触过敏原的环境因素等的认识不断提高，正在推动对氯雷他定糖浆市场的需求。

市场按年龄分为成人产品和儿童产品。 在预测期内，儿科类别将表现出更高的复合年增长率。 这主要是由于儿童过敏和花粉热的高发病率、对儿童安全药物的考虑以及长效製剂。 例如，2021年，美国约有8100万人被诊断患有季节性过敏性鼻炎（花粉症）。 这相当于大约 26% 的成年人（6700 万人）和 19% 的儿童（1400 万人）。

根据适应症，市场分为过敏性鼻炎和荨麻疹。 其中，过敏性鼻炎在2021年占据了很大的市场份额。 这主要是由于政府机构投资和资助活动的增加以及全球过敏性鼻炎患病率的上升。 例如，根据美国国立卫生研究院 (NIH) 的数据，大约 3.39 亿人患有哮喘，2 亿至 2.5 亿人患有食物过敏，4 亿人患有鼻炎。

根据药物类型，氯雷他定糖浆市场分为品牌药和仿製药。 在预测期内，氯雷他定糖浆的高采用率将属于品牌产品类别。 这主要是因为药企在营销和品牌上投入了大量资金，而且忠诚度很高。 此外，品牌药物通常是第一个进入市场的版本，并且这个特定版本已经过仔细的测试，以向消费者保证其有效性。

为了更好地了解氯雷他定糖浆行业的市场介绍，将市场分为北美（美国、加拿大和北美其他地区）、欧洲（德国、英国、法国、西班牙、意大利和其他地区）欧洲） 、亚太地区（中国、日本、印度、亚太其他地区）和世界其他国家。 预计北美在预测期内将以显着的复合年增长率增长。 由于该地区人口众多、城市化和工业化程度较高，过敏病例不断增加。 由于环境因素，亚太地区过敏性鼻炎的患病率也很高。 例如，根据国家医学图书馆 (NLM) 发表的一篇论文，印度人口超过 13.5 亿，占世界人口的近 20%。 在慢性病中，过去几年，过敏性鼻炎（AR）和哮喘等过敏性疾病在印度似乎呈上升趋势。 目前该地区大约 22% 的成年人患有过敏性鼻炎 (AR)。 因此，对氯雷他定糖浆等有效的过敏缓解药物的需求不断增长。 在中国、印度和日本等国家，不断壮大的中产阶级、不断上涨的医疗成本以及不断改善的医疗基础设施正在推动市场增长。 此外，在亚太地区的几个国家，氯雷他定糖浆作为非处方药出售，使消费者可以轻鬆获得。

目录

第一章市场介绍

• 市场定义
• 主要目的
• 利益相关者
• 限制

第二章研究方法或假设

• 调查过程
• 调查方法
• 受访者简介

第三章市场总结

第 4 章执行摘要

第五章 COVID-19 对氯雷他定糖浆市场的影响

第 6 章 2020-2030 年氯雷他定糖浆市场收入

第 7 章按年龄划分的市场洞察

• 成人使用
• 儿童

第 8 章按指标划分的市场洞察

• 过敏性鼻炎
• 荨麻疹

第 9 章按药品类型划分的市场洞察

• 品牌
• 通用

第 10 章按地区划分的市场洞察

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区

第11章氯雷他定糖浆市场动态

• 市场驱动因素
• 市场挑战
• 影响分析

第12章氯雷他定糖浆市场机会

第13章氯雷他定糖浆市场趋势

第14章需求侧和供给侧分析

• 需求方分析
• 供给侧分析

第 15 章价值链分析

第16章价格分析

第 17 章战略洞察

第18章竞争场景

• 竞争状况
  • 波特五力分析

第19章公司简介

• Merck KGaA
• Cadila Pharmaceuticals
• Medico Remedies Limited
• Sun Pharmaceutical Industries Ltd.
• GSK plc.
• Perrigo Company plc,
• Novartis AG
• Taro Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Bayer Inc.

第20章 免责事项

Loratadine syrup is a medication used to provide relief from allergy symptoms. This is known for its non-drowsy formula, making it suitable for daytime use without causing significant sedation. It effectively alleviates symptoms like sneezing, runny nose, itching, and watery eyes associated with allergies, providing long-lasting relief. The syrup formulation offers convenience, particularly for pediatric populations or individuals who have difficulty swallowing pills, as it allows for easy administration and accurate dosing. The loratadine syrup market is experiencing steady growth and is driven by several key factors such as the increasing prevalence of allergies, such as seasonal allergies, hay fever, and allergic rhinitis, which has fueled the demand for loratadine syrup. For instance, according to an article published by a U.S. organization, 339 million are suffering from asthma, 200 to 250 million have a food allergy and 400 million have rhinitis globally.

The loratadine syrup market is expected to grow at a steady rate of around 2% owing to Its over-the-counter availability, favorable safety profile, and non-drowsy formula making it a preferred choice for consumers across different age groups. Moreover, the growing awareness about allergies and their impact on health, coupled with the urbanization and environmental factors contributing to allergen exposure, has bolstered the market demand for loratadine syrup.

Based on age, the market is segmented into adult and pediatric. The pediatric category is to witness a higher CAGR during the forecast period. This is mainly due to the high prevalence of allergies and hay fever in children, consider a safe medication for children and long-acting formulations. For instance, in 2021, around 81 million people in the U.S. were diagnosed with seasonal allergic rhinitis (hay fever). This equals around 26% (67 million) of adults and 19% (14 million) of children.

On the basis of indication, the market is categorized into allergic rhinitis and urticaria. Among these, allergic rhinitis held a significant share of the market in 2021. This is mainly due to the growing investment & funding activities by government bodies and the rising prevalence of allergic rhinitis all over the world. For instance, as per the National Institutes of Health (NIH), around 339 million are suffering from asthma, 200 to 250 million have a food allergy and 400 million have rhinitis globally.

Based on drug type, the loratadine syrup market has been classified into branded and generic. The branded category is to witness higher adoption of loratadine syrup during the forecast period. This is mainly due to the pharmaceutical companies spending on marketing & branding and their loyalty being higher. Also, brand-name pills are usually the first version of the drug on the market, and this specific version has undergone careful testing to ensure efficacy to consumers.

For a better understanding of the market adoption of the loratadine syrup industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. the large population, coupled with increasing urbanization and industrialization, has led to a rise in allergy cases in the region. APAC also experiences a higher prevalence of allergic rhinitis due to environmental factors. For instance, as per an article published by the National Library of Medicine (NLM), with more than 1.35 billion people, India is home to nearly 20% of the global population. Of all chronic diseases, allergic diseases such as allergic rhinitis (AR) and asthma seem to increase in India over the past few years. Approximately, 22% of adults at present experience allergic rhinitis (AR) in the region. As a result, there is an increasing demand for effective allergy relief medications like loratadine syrup. The growing middle class, rising healthcare expenditure, and improving healthcare infrastructure in countries like China, India, and Japan contribute to the market growth. Additionally, the availability of loratadine syrup as an OTC medication in several countries within the APAC region makes it easily accessible to consumers.

Some of the major players operating in the market include: Merck KGaA; Cadila Pharmaceuticals; Medico Remedies Limited; Sun Pharmaceutical Industries Ltd.; GSK plc.; Perrigo Company plc; Novartis AG; Taro Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; and Bayer Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Loratadine Syrup Market
• 2.2. Research Methodology of the Loratadine Syrup Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE LORATADINE SYRUP MARKET

6 LORATADINE SYRUP MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY AGE

• 7.1. Adult
• 7.2. Pediatric

8 MARKET INSIGHTS BY INDICATION

• 8.1. Allergic Rhinitis
• 8.2. Urticaria

9 MARKET INSIGHTS BY DRUG TYPE

• 9.1. Branded
• 9.2. Generic

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 LORATADINE SYRUP MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 LORATADINE SYRUP MARKET OPPORTUNITIES

13 LORATADINE SYRUP MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

• 19.1. Merck KGaA
• 19.2. Cadila Pharmaceuticals
• 19.3. Medico Remedies Limited
• 19.4. Sun Pharmaceutical Industries Ltd.
• 19.5. GSK plc.
• 19.6. Perrigo Company plc,
• 19.7. Novartis AG
• 19.8. Taro Pharmaceutical Industries Ltd.
• 19.9. Dr. Reddy's Laboratories Ltd.
• 19.10. Bayer Inc.

20 DISCLAIMER